Needle Free Injections Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report Download FREE Resources

Published: July 16, 2024 Report Code: GDME1774EPD-ST

Select Item

Needle Free Injections Pipeline Market Report Overview

Needle free injections are devices that do not use a needle to administer medication. The needle free injections pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Territories ·       United States

·       Europe

·       Canada

·       Mexico

·       Others
Key Regulatory Paths ·       510(k)

·       CE

·       MDL

·       EUA

·       TGA
Leading Companies ·       aVaxziPen Limited

·       Boston Scientific Corp

·       Crossject SA

·       Enable Injections Inc

·       Eternity Healthcare Inc
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Needle Free Injections Pipeline Market Segmentation by Territories

A few of the key territories for needle free injections pipeline products are the US, Europe, Canada, and Mexico among others. As of July 2024, the US accounts for the highest number of needle free injections pipeline products.

Needle Free Injections Pipeline Market Analysis by Territories, 2024 (%)

Needle Free Injections Pipeline Market Analysis by Territories, 2024 (%)

Buy the Full Report for More Territory Insights into the Needle Free Injections Pipeline Market

Download a Free Report Sample

Needle Free Injections Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths followed by the needle free injections pipeline market are 510(k), CE, MDL, EUA, and TGA. As of July 2024, 510(k) is the most followed pathway for pipeline products in the market.

Needle Free Injections Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Needle Free Injections Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Buy the Full Report for More Regulatory Path Insights into the Needle Free Injections Pipeline Market

Download a Free Report Sample

Needle Free Injections Pipeline Market – Competitive Landscape

A few of the key companies associated with the needle free injections pipeline market are aVaxziPen Limited, Boston Scientific Corp, Crossject SA, Enable Injections Inc., and Eternity Healthcare Inc. among others.

Boston Scientific Corp: Boston Scientific is a medical technology company that develops, manufactures, and commercializes devices for a range of interventional medical specialties. The company offers products in the areas of electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, urology, and vascular surgery. Boston Scientific serves hospitals, clinics, outpatient facilities, and medical offices across the world. The company has manufacturing facilities in the US, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. It sells products directly and through a network of distributors and dealers in Europe, the Middle East, Africa, Asia Pacific, and the Americas. Boston Scientific is headquartered in Marlborough, Massachusetts, the US.

Needle Free Injections Pipeline Market Analysis by Companies, 2024

Needle Free Injections Pipeline Market Analysis by Companies, 2024

Buy the Full Report for More Company Insights into the Needle Free Injections Pipeline Market

Download a Free Report Sample

Segments Covered in the Report

Needle Free Injections Pipeline Market Territories Outlook

  • United States
  • Europe
  • Global
  • Canada
  • Mexico

Needle Free Injections Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • CE
  • MDL
  • EUA
  • TGA

Scope

This report provides:

  • Extensive coverage of the needle free injections under development.

  • The exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.

  • Reviews of major players involved in the development of needle free injections and lists all their pipeline projects.

  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.

  • Key clinical trial data of ongoing clinical trials specific to pipeline products.

  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.

  • Identify and understand important and diverse types of needle free injections under development.

  • Develop market-entry and market-expansion strategies.

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.

  • Carry out In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

aVaxziPen Limited
Boston Scientific Corp
Crossject SA
Enable Injections Inc
Eternity Healthcare Inc
Inovio Pharmaceuticals Inc
Medical International Technologies (Mit Canada) Inc
PharmaJet Inc
Teva Pharmaceutical Industries Ltd

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 7

2 Introduction 8

2.1 Needle Free Injections Overview 8

3 Products under Development 9

3.1 Needle Free Injections – Pipeline Products by Stage of Development 9

3.2 Needle Free Injections – Pipeline Products by Territory 10

3.3 Needle Free Injections – Pipeline Products by Regulatory Path 11

3.4 Needle Free Injections – Pipeline Products by Estimated Approval Date 12

4 Needle Free Injections – Pipeline Products under Development by Companies 13

4.1 Needle Free Injections Companies – Pipeline Products by Stage of Development 13

4.2 Needle Free Injections – Pipeline Products by Stage of Development 14

5 Needle Free Injections Companies and Product Overview 15

5.1 aVaxziPen Limited Company Overview 15

5.1.1 aVaxziPen Limited Pipeline Products & Ongoing Clinical Trials Overview 15

5.2 Boston Scientific Corp Company Overview 16

5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

5.3 Crossject SA Company Overview 17

5.3.1 Crossject SA Pipeline Products & Ongoing Clinical Trials Overview 17

5.4 Enable Injections Inc Company Overview 25

5.4.1 Enable Injections Inc Pipeline Products & Ongoing Clinical Trials Overview 25

5.5 Eternity Healthcare Inc Company Overview 27

5.5.1 Eternity Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.6 Inovio Pharmaceuticals Inc Company Overview 28

5.6.1 Inovio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 28

5.7 Medical International Technologies (Mit Canada) Inc Company Overview 34

5.7.1 Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 34

5.8 PharmaJet Inc Company Overview 37

5.8.1 PharmaJet Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.9 Teva Pharmaceutical Industries Ltd Company Overview 39

5.9.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 39

6 Needle Free Injections- Recent Developments 40

6.1 Jun 27, 2024: PharmaJet Needle-free System Selected for WHO Polio Immunization Campaign in Somalia 40

6.2 Jun 13, 2024: Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen (Patented Nicotinamide Riboside Chloride or Nrc) 40

6.3 May 30, 2024: Crossject Announces Publication of Clinical Data on Zepizure in Neurology and Therapy 41

6.4 May 08, 2024: Merck to Participate in the Bank of America Securities 2024 Healthcare Conference 42

6.5 May 08, 2024: Teva Pharmaceutical Industries Reports Earnings Results for the First Quarter Ended March 31, 2024 42

6.6 May 07, 2024: Baxter to Present at Bank of America 2024 Health Care Conference 42

6.7 May 02, 2024: Crossject signs a geographic extension of ZEPIZURE commercialization agreement in Europe 42

6.8 Apr 25, 2024: Merck Announces First-Quarter 2024 Financial Results 43

6.9 Apr 24, 2024: Nature Publication Highlights the Benefits of Tropis Intradermal when used to Administer a First-In-Class Self-Amplifying MRNA Vaccine 46

6.10 Apr 23, 2024: ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call 47

6.11 Apr 17, 2024: Carclo plc Welcomes New Board Member 47

6.12 Apr 10, 2024: Sichuan Kelun Pharmaceutical Reports Earnings Results for the Full Year Ended December 31, 2023 47

6.13 Apr 01, 2024: Industry Veteran Joins Merck as New EVP, Chief HR Officer 48

6.14 Feb 29, 2024: ICU Medical Board Member Resigns, Retires from Smiths Group 48

6.15 Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company 48

6.16 Feb 28, 2024: Crossject Advances in its U.S. Strategy and Reports Financial Results for 2023 48

6.17 Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering 52

6.18 Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent 52

6.19 Feb 14, 2024: Enable Injections Announces Plans to Expand Manufacturing Facilities and Corporate Headquarters 52

6.20 Feb 08, 2024: Baxter Reports Fourth-Quarter and Full-Year 2023 Results 53

6.21 Feb 07, 2024: Terumo Announces Change of Executive Officers (PDF

232.27 KB) 56

6.22 Feb 01, 2024: Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results 56

6.23 Jan 19, 2024: Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1 60

6.24 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results 61

6.25 Jan 04, 2024: Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE 61

6.26 Jan 04, 2024: Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors 61

6.27 Jan 03, 2024: Medytox Announces Executive Appointments in Luvantas, Inc 62

6.28 Dec 22, 2023: Crossject Signs Zepizure Commercialization Agreement for Northern Europe 62

6.29 Nov 28, 2023: Alchemy 43, Rapidly Expanding Aesthetics Brand, Now Offering GLP-1 Injections for Weight Management 62

6.30 Nov 07, 2023: Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business 63

6.31 Nov 03, 2023: Jabil Reports Changes to Board of Directors 63

6.32 Nov 03, 2023: Jabil Announces Upcoming Changes to the Board of Directors 64

6.33 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023 65

6.34 Oct 03, 2023: Baxter Appoints Joel Grade Chief Financial Officer 66

6.35 Oct 02, 2023: Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval 67

6.36 Sep 28, 2023: Teva Announces Changes to Executive Management Team 67

6.37 Sep 19, 2023: Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors 68

6.38 Aug 21, 2023: Carclo Appoints Eric Hutchinson as New CFO 68

6.39 Aug 10, 2023: Medytox Appoints Director Kim Jae-wook to Oversee Medical Division 69

6.40 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility 69

6.41 Jul 12, 2023: Carclo Announces Unaudited Preliminary Results for the year ended 31 March 2023 69

7 Appendix 71

7.1 Methodology 71

7.2 About GlobalData 74

7.3 Contact Us 74

7.4 Disclaimer 74

Table

Needle Free Injections – Pipeline Products by Stage of Development 9

Needle Free Injections – Pipeline Products by Territory 10

Needle Free Injections – Pipeline Products by Regulatory Path 11

Needle Free Injections – Pipeline Products by Estimated Approval Date 12

Needle Free Injections Companies – Pipeline Products by Stage of Development 13

Needle Free Injections – Pipeline Products by Stage of Development 14

aVaxziPen Limited Pipeline Products & Ongoing Clinical Trials Overview 15

Enesi ImplaVax System – Product Status 15

Enesi ImplaVax System – Product Description 15

Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16

JetTouch System – Overactive Bladder – Product Status 16

JetTouch System – Overactive Bladder – Product Description 16

Crossject SA Pipeline Products & Ongoing Clinical Trials Overview 17

Zeneo Epinephrine Auto Injector – Product Status 17

Zeneo Epinephrine Auto Injector – Product Description 18

Zeneo ID Human Needle-Free Injection Device – Product Status 18

Zeneo ID Human Needle-Free Injection Device – Product Description 18

Zeneo IM 0.5ml Needle-Free Injection Device – Product Status 19

Zeneo IM 0.5ml Needle-Free Injection Device – Product Description 19

Zeneo Naloxone Auto Injector – Product Status 19

Zeneo Naloxone Auto Injector – Product Description 20

Zeneo SC 0.5ml Needle-Free Injection Device – Product Status 20

Zeneo SC 0.5ml Needle-Free Injection Device – Product Description 20

Zeneo SC 0.8ml Needle-Free Injection Device – Product Status 21

Zeneo SC 0.8ml Needle-Free Injection Device – Product Description 21

Zeneo SC High Viscosity Needle-Free Injection Device – Product Status 21

Zeneo SC High Viscosity Needle-Free Injection Device – Product Description 22

Zeneo Sumatriptan Auto Injector – Product Status 22

Zeneo Sumatriptan Auto Injector – Product Description 22

Zeneo Terbutaline Auto Injector – Product Status 23

Zeneo Terbutaline Auto Injector – Product Description 23

ZEPIZURE – Product Status 23

ZEPIZURE – Product Description 24

Enable Injections Inc Pipeline Products & Ongoing Clinical Trials Overview 25

Enfuse Differentiated Molecular Drug Delivery System – Product Status 25

Enfuse Differentiated Molecular Drug Delivery System – Product Description 25

enFuse On-Body Infusor – Product Status 26

enFuse On-Body Infusor – Product Description 26

Eternity Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Multi Channel Needle-Free Injection Device – Product Status 27

Multi Channel Needle-Free Injection Device – Product Description 27

Inovio Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 28

Iject Pre-Filled Syringe – Product Status 28

Iject Pre-Filled Syringe – Product Description 29

Iject R Pre-Filled Syringe – Product Status 29

Iject R Pre-Filled Syringe – Product Description 29

Intradermal Pen Injector – Product Status 30

Intradermal Pen Injector – Product Description 30

Intradermal Syringe – Product Status 30

Intradermal Syringe – Product Description 31

Mega Jet – Product Status 31

Mega Jet – Product Description 31

Multi-Port Orifices – Product Status 32

Multi-Port Orifices – Product Description 32

Needle-Free Vaccine Delivery Device – Product Status 32

Needle-Free Vaccine Delivery Device – Product Description 33

Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview 34

MIT-H-IV-1 – Product Status 34

MIT-H-IV-1 – Product Description 34

MIT-H-IV-5 – Product Status 35

MIT-H-IV-5 – Product Description 35

MIT-H-VI Dental Injector – Product Status 35

MIT-H-VI Dental Injector – Product Description 36

PharmaJet Inc Pipeline Products & Ongoing Clinical Trials Overview 37

Pre-filled Syringe – Product Status 37

Pre-filled Syringe – Product Description 37

Variable Volume Drug Delivery Device – Product Status 38

Variable Volume Drug Delivery Device – Product Description 38

Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 39

MicroDose Needlefree System – Product Status 39

MicroDose Needlefree System – Product Description 39

Glossary 73

Figures

Needle Free Injections – Pipeline Products by Stage of Development 9

Needle Free Injections – Pipeline Products by Territory 10

Needle Free Injections – Pipeline Products by Regulatory Path 11

Needle Free Injections – Pipeline Products by Estimated Approval Date 12

Frequently asked questions

Needle Free Injections Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Needle Free Injections Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Needle Free Injections reports
Medical Devices
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Medical Devices
New
Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…
$495 | July 2026
Medical Devices
New
AI-designed Materials: Market Trends and Innovations
$995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Needle Free Injections Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Needle Free Injections Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more